MedTrace Logo

Sildenafil in Sever Intrauterine Growth Retardation

NCT03153215 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2018-07-10

No results posted yet for this study

Summary

Severe fetal growth restriction (FGR) complicates approximately 0.4% of pregnancies and severely increases the risk of perinatal morbidity and mortality.Sildenafil citrate may offer a potential therapeutic strategy to improve uteroplacental blood flow in IUGR pregnancies.

Conditions

  • Intra-Uterine Growth Retardation

Interventions

OTHER

treatment

We will offer Sildenafil citrate (20 mg per os three times daily until delivery) as innovative therapy to 23 women with severe IUGR ('Sildenafil-treated') in addition to fish oil and zinc supplementation.

OTHER

Placebo

Placebo tablets similar to Sildenafil will be given to control group in addition to fish oil and zinc supplementation.

Sponsors & Collaborators

  • Cairo University

    collaborator OTHER

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Nesreen A Shehata, MD · Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-06
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • Egypt

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03153215 on ClinicalTrials.gov